| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gambling | 153 | 2026 | 169 | 43.200 |
Why?
|
| Trichotillomania | 93 | 2026 | 99 | 37.890 |
Why?
|
| Obsessive-Compulsive Disorder | 96 | 2026 | 165 | 27.130 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 116 | 2025 | 290 | 23.320 |
Why?
|
| Impulsive Behavior | 91 | 2026 | 296 | 22.060 |
Why?
|
| Behavior, Addictive | 60 | 2026 | 140 | 17.600 |
Why?
|
| Compulsive Behavior | 61 | 2026 | 87 | 17.320 |
Why?
|
| Self-Injurious Behavior | 36 | 2025 | 119 | 13.610 |
Why?
|
| Comorbidity | 97 | 2026 | 1033 | 9.250 |
Why?
|
| Young Adult | 190 | 2026 | 7556 | 8.720 |
Why?
|
| Adult | 348 | 2026 | 29548 | 8.530 |
Why?
|
| Students | 23 | 2022 | 197 | 7.770 |
Why?
|
| Skin | 33 | 2025 | 591 | 7.430 |
Why?
|
| Mental Disorders | 41 | 2026 | 486 | 6.930 |
Why?
|
| Substance-Related Disorders | 42 | 2023 | 470 | 6.820 |
Why?
|
| Adolescent | 167 | 2026 | 10127 | 6.590 |
Why?
|
| Male | 345 | 2026 | 47195 | 6.390 |
Why?
|
| Cognition | 36 | 2024 | 669 | 6.380 |
Why?
|
| Female | 359 | 2026 | 51685 | 6.240 |
Why?
|
| Humans | 509 | 2026 | 98223 | 6.200 |
Why?
|
| Internet | 26 | 2026 | 358 | 6.130 |
Why?
|
| Psychiatric Status Rating Scales | 66 | 2026 | 508 | 5.880 |
Why?
|
| Naltrexone | 31 | 2025 | 139 | 5.880 |
Why?
|
| Narcotic Antagonists | 32 | 2025 | 181 | 5.500 |
Why?
|
| Cognition Disorders | 19 | 2026 | 239 | 5.180 |
Why?
|
| Anxiety Disorders | 30 | 2024 | 160 | 4.990 |
Why?
|
| Sexual Behavior | 23 | 2023 | 340 | 4.970 |
Why?
|
| Neuropsychological Tests | 50 | 2026 | 567 | 4.920 |
Why?
|
| Executive Function | 14 | 2026 | 115 | 4.880 |
Why?
|
| Borderline Personality Disorder | 8 | 2026 | 45 | 4.660 |
Why?
|
| Quality of Life | 42 | 2024 | 1897 | 4.320 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 42 | 2023 | 226 | 4.290 |
Why?
|
| Middle Aged | 197 | 2026 | 29494 | 4.280 |
Why?
|
| Personality | 17 | 2024 | 139 | 4.200 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 12 | 2024 | 195 | 4.160 |
Why?
|
| Severity of Illness Index | 65 | 2025 | 2012 | 3.870 |
Why?
|
| Compulsive Personality Disorder | 14 | 2023 | 16 | 3.720 |
Why?
|
| Acetylcysteine | 10 | 2025 | 73 | 3.670 |
Why?
|
| Alcoholism | 18 | 2025 | 200 | 3.640 |
Why?
|
| Surveys and Questionnaires | 67 | 2026 | 3030 | 3.620 |
Why?
|
| Decision Making | 23 | 2020 | 689 | 3.410 |
Why?
|
| Personality Disorders | 17 | 2024 | 145 | 3.410 |
Why?
|
| Universities | 21 | 2022 | 166 | 3.170 |
Why?
|
| Depression | 20 | 2024 | 618 | 2.850 |
Why?
|
| Cognitive Dysfunction | 8 | 2020 | 209 | 2.610 |
Why?
|
| Risk-Taking | 10 | 2020 | 159 | 2.490 |
Why?
|
| Body Dysmorphic Disorders | 9 | 2019 | 12 | 2.450 |
Why?
|
| Prevalence | 35 | 2026 | 1391 | 2.380 |
Why?
|
| Anxiety | 17 | 2024 | 370 | 2.380 |
Why?
|
| Double-Blind Method | 40 | 2024 | 1787 | 2.360 |
Why?
|
| Memory, Short-Term | 12 | 2026 | 258 | 2.360 |
Why?
|
| Psychotropic Drugs | 10 | 2020 | 82 | 2.350 |
Why?
|
| Biomedical Research | 10 | 2020 | 471 | 2.300 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2024 | 69 | 2.270 |
Why?
|
| Cerebral Cortex | 8 | 2021 | 573 | 2.100 |
Why?
|
| Cost-Benefit Analysis | 4 | 2026 | 525 | 1.990 |
Why?
|
| Memantine | 6 | 2023 | 10 | 1.990 |
Why?
|
| Treatment Outcome | 59 | 2026 | 9750 | 1.950 |
Why?
|
| Silymarin | 3 | 2024 | 3 | 1.860 |
Why?
|
| Theft | 6 | 2017 | 12 | 1.860 |
Why?
|
| Aged | 79 | 2026 | 21824 | 1.840 |
Why?
|
| Patient Dropouts | 3 | 2025 | 33 | 1.810 |
Why?
|
| Mental Health | 12 | 2024 | 219 | 1.800 |
Why?
|
| Brain | 24 | 2025 | 2431 | 1.750 |
Why?
|
| Alcohol-Related Disorders | 5 | 2020 | 18 | 1.740 |
Why?
|
| Prescription Drug Misuse | 3 | 2020 | 14 | 1.730 |
Why?
|
| Reward | 14 | 2023 | 228 | 1.730 |
Why?
|
| Interview, Psychological | 10 | 2018 | 70 | 1.640 |
Why?
|
| Sex Factors | 25 | 2024 | 1142 | 1.620 |
Why?
|
| Alcohol Drinking | 8 | 2019 | 301 | 1.590 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2025 | 3611 | 1.560 |
Why?
|
| Cross-Sectional Studies | 28 | 2026 | 2054 | 1.550 |
Why?
|
| Clinical Trials as Topic | 10 | 2025 | 1126 | 1.540 |
Why?
|
| Central Nervous System Stimulants | 5 | 2018 | 246 | 1.540 |
Why?
|
| Suicide, Attempted | 7 | 2024 | 145 | 1.540 |
Why?
|
| Firesetting Behavior | 5 | 2018 | 5 | 1.520 |
Why?
|
| Psychometrics | 23 | 2024 | 356 | 1.510 |
Why?
|
| Antidepressive Agents | 6 | 2019 | 118 | 1.470 |
Why?
|
| Frontal Lobe | 8 | 2015 | 128 | 1.470 |
Why?
|
| Age of Onset | 18 | 2024 | 368 | 1.470 |
Why?
|
| Somatoform Disorders | 8 | 2006 | 31 | 1.460 |
Why?
|
| Binge-Eating Disorder | 4 | 2021 | 86 | 1.450 |
Why?
|
| Obsessive Behavior | 4 | 2021 | 8 | 1.450 |
Why?
|
| International Classification of Diseases | 5 | 2024 | 74 | 1.440 |
Why?
|
| Psychotherapy | 9 | 2021 | 76 | 1.430 |
Why?
|
| Dronabinol | 3 | 2022 | 60 | 1.430 |
Why?
|
| Family | 6 | 2024 | 328 | 1.430 |
Why?
|
| Placebo Effect | 4 | 2024 | 37 | 1.410 |
Why?
|
| Spatial Memory | 2 | 2026 | 30 | 1.380 |
Why?
|
| Depressive Disorder | 11 | 2016 | 231 | 1.360 |
Why?
|
| Sexual Dysfunctions, Psychological | 4 | 2022 | 37 | 1.350 |
Why?
|
| Implosive Therapy | 5 | 2022 | 9 | 1.320 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2018 | 168 | 1.310 |
Why?
|
| Antipsychotic Agents | 6 | 2020 | 166 | 1.310 |
Why?
|
| Research Support as Topic | 2 | 2026 | 97 | 1.300 |
Why?
|
| Tobacco Use Disorder | 5 | 2018 | 130 | 1.300 |
Why?
|
| Corpus Striatum | 6 | 2024 | 83 | 1.280 |
Why?
|
| Feeding and Eating Disorders | 6 | 2025 | 190 | 1.270 |
Why?
|
| Excitatory Amino Acid Agents | 3 | 2025 | 6 | 1.260 |
Why?
|
| Problem Solving | 2 | 2026 | 59 | 1.240 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2021 | 29 | 1.240 |
Why?
|
| Deep Brain Stimulation | 4 | 2016 | 89 | 1.230 |
Why?
|
| Self Report | 16 | 2023 | 357 | 1.220 |
Why?
|
| Erotica | 3 | 2024 | 5 | 1.200 |
Why?
|
| United States | 33 | 2026 | 8252 | 1.190 |
Why?
|
| Obesity | 7 | 2016 | 1076 | 1.180 |
Why?
|
| Sexual and Gender Minorities | 2 | 2023 | 262 | 1.170 |
Why?
|
| Desensitization, Psychologic | 4 | 2014 | 4 | 1.140 |
Why?
|
| Antisocial Personality Disorder | 5 | 2017 | 92 | 1.140 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2016 | 93 | 1.130 |
Why?
|
| Methamphetamine | 3 | 2021 | 111 | 1.120 |
Why?
|
| Personality Inventory | 13 | 2024 | 112 | 1.080 |
Why?
|
| Emotions | 7 | 2023 | 387 | 1.070 |
Why?
|
| United Kingdom | 17 | 2026 | 211 | 1.070 |
Why?
|
| Attention | 7 | 2023 | 435 | 1.060 |
Why?
|
| Machine Learning | 3 | 2023 | 408 | 1.050 |
Why?
|
| Reaction Time | 9 | 2018 | 318 | 1.040 |
Why?
|
| Minnesota | 13 | 2017 | 64 | 1.030 |
Why?
|
| Criminals | 2 | 2017 | 35 | 1.030 |
Why?
|
| Paraphilic Disorders | 3 | 2021 | 3 | 1.020 |
Why?
|
| Autistic Disorder | 3 | 2023 | 155 | 1.020 |
Why?
|
| Choice Behavior | 7 | 2016 | 164 | 0.980 |
Why?
|
| Body Image | 6 | 2024 | 87 | 0.970 |
Why?
|
| Homosexuality | 2 | 2020 | 10 | 0.970 |
Why?
|
| Sexuality | 2 | 2019 | 40 | 0.960 |
Why?
|
| Financing, Organized | 1 | 2026 | 14 | 0.960 |
Why?
|
| Psilocybin | 1 | 2026 | 5 | 0.950 |
Why?
|
| Peer Review, Research | 1 | 2026 | 41 | 0.950 |
Why?
|
| Case-Control Studies | 13 | 2024 | 2002 | 0.940 |
Why?
|
| Self Concept | 6 | 2024 | 140 | 0.930 |
Why?
|
| Exhibitionism | 2 | 2021 | 3 | 0.930 |
Why?
|
| Pilot Projects | 14 | 2026 | 970 | 0.920 |
Why?
|
| Homosexuality, Female | 2 | 2023 | 17 | 0.900 |
Why?
|
| Caffeine | 2 | 2017 | 86 | 0.890 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2018 | 314 | 0.890 |
Why?
|
| Marijuana Use | 1 | 2025 | 13 | 0.890 |
Why?
|
| Serotonin Agents | 1 | 2025 | 14 | 0.880 |
Why?
|
| Phenelzine | 2 | 2023 | 2 | 0.880 |
Why?
|
| Analysis of Variance | 11 | 2017 | 889 | 0.870 |
Why?
|
| Benzophenones | 4 | 2024 | 16 | 0.870 |
Why?
|
| Overweight | 2 | 2016 | 128 | 0.860 |
Why?
|
| Nail Biting | 5 | 2017 | 5 | 0.860 |
Why?
|
| Thiophenes | 1 | 2024 | 46 | 0.850 |
Why?
|
| Psychological Tests | 5 | 2021 | 89 | 0.850 |
Why?
|
| Quinolones | 1 | 2024 | 57 | 0.840 |
Why?
|
| Longitudinal Studies | 13 | 2024 | 1295 | 0.830 |
Why?
|
| Hallucinogens | 1 | 2026 | 92 | 0.830 |
Why?
|
| Drug Resistance | 4 | 2021 | 233 | 0.830 |
Why?
|
| Smoking | 6 | 2016 | 676 | 0.830 |
Why?
|
| Nitrophenols | 3 | 2013 | 11 | 0.820 |
Why?
|
| Video Games | 3 | 2020 | 14 | 0.810 |
Why?
|
| Pandemics | 6 | 2022 | 913 | 0.810 |
Why?
|
| Age Factors | 15 | 2018 | 1972 | 0.810 |
Why?
|
| Problem Behavior | 3 | 2020 | 11 | 0.790 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2013 | 78 | 0.780 |
Why?
|
| Reproducibility of Results | 22 | 2025 | 2789 | 0.770 |
Why?
|
| Health Facilities | 1 | 2023 | 43 | 0.760 |
Why?
|
| Personality Assessment | 9 | 2012 | 99 | 0.760 |
Why?
|
| Stereotypic Movement Disorder | 3 | 2014 | 6 | 0.760 |
Why?
|
| Exercise | 2 | 2026 | 382 | 0.760 |
Why?
|
| Statistics as Topic | 6 | 2016 | 229 | 0.750 |
Why?
|
| Motivation | 11 | 2024 | 344 | 0.740 |
Why?
|
| Pregnancy Complications | 1 | 2025 | 368 | 0.730 |
Why?
|
| Suicide | 3 | 2014 | 176 | 0.730 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 132 | 0.730 |
Why?
|
| Adolescent Behavior | 4 | 2011 | 118 | 0.720 |
Why?
|
| South Africa | 11 | 2023 | 63 | 0.720 |
Why?
|
| Models, Neurological | 2 | 2015 | 411 | 0.720 |
Why?
|
| Temperament | 4 | 2024 | 29 | 0.710 |
Why?
|
| Models, Psychological | 4 | 2019 | 166 | 0.710 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2020 | 46 | 0.700 |
Why?
|
| Cost of Illness | 2 | 2020 | 165 | 0.700 |
Why?
|
| Dopamine Agents | 2 | 2020 | 33 | 0.700 |
Why?
|
| Liability, Legal | 1 | 2022 | 27 | 0.700 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 4041 | 0.700 |
Why?
|
| Cold Temperature | 3 | 2019 | 162 | 0.690 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 1946 | 0.690 |
Why?
|
| Behavioral Symptoms | 1 | 2021 | 15 | 0.680 |
Why?
|
| Methylphenidate | 2 | 2018 | 11 | 0.680 |
Why?
|
| Craving | 1 | 2021 | 30 | 0.680 |
Why?
|
| Evidence-Based Practice | 2 | 2020 | 54 | 0.670 |
Why?
|
| Stress, Psychological | 4 | 2016 | 384 | 0.660 |
Why?
|
| Disease Progression | 5 | 2019 | 1612 | 0.660 |
Why?
|
| Crisis Intervention | 1 | 2021 | 13 | 0.660 |
Why?
|
| Child | 19 | 2025 | 7730 | 0.650 |
Why?
|
| Anticonvulsants | 1 | 2021 | 134 | 0.640 |
Why?
|
| Bisexuality | 3 | 2023 | 36 | 0.630 |
Why?
|
| Minority Groups | 4 | 2023 | 158 | 0.630 |
Why?
|
| Ownership | 1 | 2020 | 30 | 0.630 |
Why?
|
| Midwestern United States | 5 | 2019 | 92 | 0.620 |
Why?
|
| Viral Vaccines | 1 | 2020 | 38 | 0.620 |
Why?
|
| Risk Factors | 16 | 2023 | 6269 | 0.620 |
Why?
|
| Gyrus Cinguli | 3 | 2020 | 56 | 0.610 |
Why?
|
| Self-Control | 2 | 2016 | 14 | 0.610 |
Why?
|
| Ketamine | 1 | 2020 | 28 | 0.610 |
Why?
|
| Charities | 2 | 2018 | 3 | 0.610 |
Why?
|
| Neuroimaging | 2 | 2018 | 143 | 0.610 |
Why?
|
| Crime | 3 | 2009 | 38 | 0.600 |
Why?
|
| Cocaine-Related Disorders | 1 | 2020 | 45 | 0.600 |
Why?
|
| Academic Performance | 1 | 2019 | 6 | 0.590 |
Why?
|
| Academic Success | 1 | 2019 | 11 | 0.590 |
Why?
|
| Deception | 1 | 2019 | 19 | 0.590 |
Why?
|
| Pain Perception | 1 | 2019 | 20 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 220 | 0.590 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 3 | 2024 | 9 | 0.580 |
Why?
|
| Cross-Cultural Comparison | 5 | 2017 | 36 | 0.580 |
Why?
|
| Suicidal Ideation | 4 | 2023 | 88 | 0.570 |
Why?
|
| Firearms | 1 | 2020 | 92 | 0.570 |
Why?
|
| Smartphone | 1 | 2019 | 53 | 0.570 |
Why?
|
| Amphetamines | 1 | 2018 | 18 | 0.570 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 140 | 0.570 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2021 | 78 | 0.560 |
Why?
|
| Dopamine | 7 | 2024 | 280 | 0.560 |
Why?
|
| Triazines | 2 | 2010 | 55 | 0.560 |
Why?
|
| Dopamine Antagonists | 2 | 2018 | 33 | 0.560 |
Why?
|
| Saliva | 2 | 2018 | 134 | 0.560 |
Why?
|
| Functional Neuroimaging | 1 | 2018 | 33 | 0.560 |
Why?
|
| Piperazines | 1 | 2020 | 307 | 0.550 |
Why?
|
| Genetic Variation | 4 | 2026 | 1452 | 0.550 |
Why?
|
| Benzazepines | 2 | 2018 | 64 | 0.550 |
Why?
|
| Phobia, Social | 1 | 2018 | 2 | 0.550 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2026 | 2569 | 0.550 |
Why?
|
| Social Behavior Disorders | 2 | 2016 | 20 | 0.540 |
Why?
|
| Pain Threshold | 2 | 2016 | 64 | 0.540 |
Why?
|
| Independent Living | 1 | 2018 | 33 | 0.540 |
Why?
|
| Judgment | 2 | 2020 | 69 | 0.540 |
Why?
|
| Financing, Government | 1 | 2018 | 26 | 0.540 |
Why?
|
| Alcohol Deterrents | 1 | 2017 | 2 | 0.540 |
Why?
|
| Educational Status | 5 | 2025 | 205 | 0.540 |
Why?
|
| Sleep | 2 | 2020 | 465 | 0.530 |
Why?
|
| Disulfiram | 1 | 2017 | 8 | 0.530 |
Why?
|
| Vaping | 1 | 2019 | 57 | 0.530 |
Why?
|
| Bibliometrics | 2 | 2015 | 49 | 0.530 |
Why?
|
| Jurisprudence | 1 | 2017 | 23 | 0.530 |
Why?
|
| Dietary Sucrose | 1 | 2017 | 14 | 0.530 |
Why?
|
| Soft Tissue Injuries | 1 | 2017 | 17 | 0.520 |
Why?
|
| Progesterone | 1 | 2018 | 126 | 0.520 |
Why?
|
| Psychotherapy, Brief | 1 | 2017 | 14 | 0.520 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 38 | 0.520 |
Why?
|
| Mental Competency | 1 | 2017 | 49 | 0.520 |
Why?
|
| Antioxidants | 1 | 2019 | 236 | 0.520 |
Why?
|
| Sleep Deprivation | 1 | 2018 | 128 | 0.520 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2017 | 1 | 0.520 |
Why?
|
| Anorexia Nervosa | 3 | 2022 | 145 | 0.510 |
Why?
|
| Corpus Callosum | 2 | 2025 | 58 | 0.510 |
Why?
|
| Paroxetine | 6 | 2009 | 26 | 0.510 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2019 | 91 | 0.510 |
Why?
|
| Behavior Therapy | 6 | 2021 | 100 | 0.510 |
Why?
|
| Neural Pathways | 3 | 2016 | 334 | 0.510 |
Why?
|
| Inositol | 1 | 2017 | 17 | 0.510 |
Why?
|
| Drugs, Investigational | 2 | 2015 | 36 | 0.510 |
Why?
|
| Drug Administration Schedule | 9 | 2016 | 836 | 0.500 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.500 |
Why?
|
| Estradiol | 1 | 2018 | 268 | 0.500 |
Why?
|
| Government | 2 | 2016 | 11 | 0.500 |
Why?
|
| Vitamin B Complex | 1 | 2017 | 22 | 0.500 |
Why?
|
| Dietary Fats | 1 | 2017 | 135 | 0.500 |
Why?
|
| Private Sector | 2 | 2016 | 23 | 0.500 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 542 | 0.490 |
Why?
|
| Combined Modality Therapy | 7 | 2015 | 1751 | 0.490 |
Why?
|
| Bipolar Disorder | 6 | 2012 | 412 | 0.490 |
Why?
|
| Testosterone | 1 | 2018 | 265 | 0.490 |
Why?
|
| Cycloserine | 1 | 2016 | 5 | 0.490 |
Why?
|
| White Matter | 2 | 2025 | 100 | 0.480 |
Why?
|
| Symptom Assessment | 1 | 2017 | 77 | 0.480 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 481 | 0.480 |
Why?
|
| Brain Infarction | 1 | 2016 | 23 | 0.480 |
Why?
|
| Veterans | 1 | 2017 | 119 | 0.480 |
Why?
|
| Genetic Testing | 5 | 2026 | 599 | 0.470 |
Why?
|
| Socioeconomic Factors | 9 | 2015 | 666 | 0.470 |
Why?
|
| Nucleus Accumbens | 5 | 2017 | 117 | 0.460 |
Why?
|
| Diagnosis, Differential | 8 | 2017 | 1569 | 0.460 |
Why?
|
| Research Personnel | 1 | 2016 | 85 | 0.460 |
Why?
|
| Habits | 5 | 2018 | 17 | 0.460 |
Why?
|
| Policy Making | 4 | 2021 | 64 | 0.450 |
Why?
|
| Biological Science Disciplines | 1 | 2015 | 14 | 0.450 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 23 | 0.450 |
Why?
|
| Research | 7 | 2022 | 257 | 0.440 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 341 | 0.440 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.440 |
Why?
|
| Hoarding Disorder | 2 | 2015 | 7 | 0.440 |
Why?
|
| Thalamus | 1 | 2016 | 136 | 0.440 |
Why?
|
| Thinking | 1 | 2015 | 40 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2570 | 0.430 |
Why?
|
| Life Change Events | 1 | 2015 | 49 | 0.430 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 303 | 0.430 |
Why?
|
| Health Expenditures | 1 | 2016 | 100 | 0.430 |
Why?
|
| Endophenotypes | 1 | 2014 | 20 | 0.420 |
Why?
|
| Marijuana Abuse | 1 | 2014 | 32 | 0.420 |
Why?
|
| Monoamine Oxidase Inhibitors | 3 | 2023 | 7 | 0.420 |
Why?
|
| Parkinson Disease | 3 | 2014 | 186 | 0.410 |
Why?
|
| Placebos | 9 | 2013 | 209 | 0.410 |
Why?
|
| Expectorants | 1 | 2014 | 5 | 0.410 |
Why?
|
| Pain | 1 | 2016 | 417 | 0.410 |
Why?
|
| Dissociative Disorders | 2 | 2004 | 9 | 0.400 |
Why?
|
| Skin Diseases | 1 | 2015 | 177 | 0.400 |
Why?
|
| Neoplasms | 5 | 2026 | 3348 | 0.400 |
Why?
|
| Organ Size | 3 | 2020 | 370 | 0.400 |
Why?
|
| Health Policy | 3 | 2021 | 217 | 0.400 |
Why?
|
| Cross-Over Studies | 6 | 2021 | 394 | 0.390 |
Why?
|
| Neurobiology | 1 | 2013 | 11 | 0.390 |
Why?
|
| Brain Mapping | 2 | 2013 | 570 | 0.380 |
Why?
|
| Parents | 2 | 2021 | 322 | 0.380 |
Why?
|
| Factor Analysis, Statistical | 6 | 2024 | 119 | 0.380 |
Why?
|
| Parenting | 3 | 2021 | 70 | 0.380 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 33 | 0.380 |
Why?
|
| Citalopram | 2 | 2017 | 22 | 0.370 |
Why?
|
| Aggression | 4 | 2018 | 341 | 0.370 |
Why?
|
| Psychomotor Performance | 6 | 2018 | 508 | 0.370 |
Why?
|
| Parietal Lobe | 1 | 2013 | 114 | 0.370 |
Why?
|
| Mood Disorders | 5 | 2024 | 86 | 0.370 |
Why?
|
| Blood Pressure | 4 | 2019 | 920 | 0.360 |
Why?
|
| Logistic Models | 4 | 2021 | 1275 | 0.360 |
Why?
|
| Antimanic Agents | 3 | 2007 | 14 | 0.360 |
Why?
|
| Violence | 1 | 2014 | 164 | 0.360 |
Why?
|
| Internal-External Control | 2 | 2009 | 47 | 0.360 |
Why?
|
| Motivational Interviewing | 3 | 2021 | 25 | 0.360 |
Why?
|
| Students, Medical | 1 | 2017 | 449 | 0.360 |
Why?
|
| Psychiatry | 4 | 2019 | 92 | 0.350 |
Why?
|
| Social Adjustment | 5 | 2015 | 46 | 0.350 |
Why?
|
| Demography | 6 | 2020 | 193 | 0.350 |
Why?
|
| Time Factors | 8 | 2020 | 5573 | 0.350 |
Why?
|
| Hair | 2 | 2022 | 56 | 0.350 |
Why?
|
| Body Mass Index | 5 | 2016 | 867 | 0.340 |
Why?
|
| Marijuana Smoking | 1 | 2011 | 32 | 0.340 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 81 | 0.340 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2011 | 11 | 0.340 |
Why?
|
| Rehabilitation, Vocational | 1 | 2011 | 4 | 0.340 |
Why?
|
| Transsexualism | 1 | 2011 | 24 | 0.340 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 523 | 0.330 |
Why?
|
| Health Surveys | 5 | 2013 | 254 | 0.330 |
Why?
|
| Phenotype | 7 | 2025 | 2653 | 0.330 |
Why?
|
| Nerve Net | 2 | 2013 | 404 | 0.330 |
Why?
|
| Antiparkinson Agents | 1 | 2010 | 18 | 0.320 |
Why?
|
| Standard of Care | 2 | 2024 | 70 | 0.320 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 118 | 0.310 |
Why?
|
| Risk Assessment | 4 | 2021 | 2598 | 0.310 |
Why?
|
| Patient Selection | 1 | 2014 | 721 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2024 | 992 | 0.300 |
Why?
|
| Child of Impaired Parents | 1 | 2009 | 20 | 0.300 |
Why?
|
| Bankruptcy | 1 | 2009 | 2 | 0.300 |
Why?
|
| Sex Characteristics | 1 | 2012 | 352 | 0.300 |
Why?
|
| Cohort Studies | 6 | 2024 | 3217 | 0.300 |
Why?
|
| Disability Evaluation | 3 | 2016 | 185 | 0.290 |
Why?
|
| Single-Blind Method | 5 | 2017 | 160 | 0.290 |
Why?
|
| Character | 1 | 2009 | 6 | 0.290 |
Why?
|
| Health Status | 4 | 2017 | 388 | 0.290 |
Why?
|
| Glutamic Acid | 2 | 2022 | 136 | 0.290 |
Why?
|
| Affective Symptoms | 2 | 2023 | 59 | 0.280 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2024 | 87 | 0.280 |
Why?
|
| Pica | 1 | 2008 | 14 | 0.280 |
Why?
|
| Retrospective Studies | 12 | 2025 | 11031 | 0.270 |
Why?
|
| Ambulatory Care | 5 | 2013 | 202 | 0.270 |
Why?
|
| Internationality | 2 | 2018 | 80 | 0.270 |
Why?
|
| Penetrance | 2 | 2024 | 51 | 0.270 |
Why?
|
| Autonomic Nervous System | 2 | 2019 | 70 | 0.260 |
Why?
|
| Brazil | 6 | 2018 | 93 | 0.260 |
Why?
|
| Motor Activity | 1 | 2009 | 328 | 0.260 |
Why?
|
| Research Design | 3 | 2018 | 650 | 0.250 |
Why?
|
| Mutation, Missense | 2 | 2025 | 302 | 0.250 |
Why?
|
| Glutamates | 2 | 2023 | 84 | 0.250 |
Why?
|
| Touch | 1 | 2007 | 53 | 0.250 |
Why?
|
| Delusions | 2 | 2006 | 12 | 0.250 |
Why?
|
| Lithium Carbonate | 1 | 2006 | 7 | 0.250 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 763 | 0.250 |
Why?
|
| State Medicine | 3 | 2025 | 15 | 0.240 |
Why?
|
| Anger | 2 | 2018 | 83 | 0.240 |
Why?
|
| Social Environment | 2 | 2011 | 199 | 0.240 |
Why?
|
| Smoking Cessation | 3 | 2022 | 310 | 0.240 |
Why?
|
| Anisotropy | 4 | 2012 | 61 | 0.240 |
Why?
|
| Heart Rate | 3 | 2019 | 534 | 0.240 |
Why?
|
| Electroconvulsive Therapy | 2 | 2007 | 26 | 0.230 |
Why?
|
| Avoidance Learning | 1 | 2025 | 23 | 0.230 |
Why?
|
| Fumarate Hydratase | 1 | 2025 | 8 | 0.230 |
Why?
|
| Internal Capsule | 2 | 2024 | 10 | 0.230 |
Why?
|
| Psychotherapy, Group | 2 | 2018 | 37 | 0.230 |
Why?
|
| Leiomyomatosis | 1 | 2025 | 15 | 0.230 |
Why?
|
| Illinois | 2 | 2017 | 524 | 0.230 |
Why?
|
| Achievement | 2 | 2016 | 30 | 0.230 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2025 | 30 | 0.230 |
Why?
|
| Endorphins | 2 | 2007 | 13 | 0.220 |
Why?
|
| Public Sector | 2 | 2016 | 14 | 0.220 |
Why?
|
| Ethanol | 2 | 2022 | 282 | 0.220 |
Why?
|
| Mental Status Schedule | 2 | 2015 | 26 | 0.220 |
Why?
|
| Linear Models | 3 | 2013 | 426 | 0.220 |
Why?
|
| Hospitalization | 3 | 2007 | 986 | 0.220 |
Why?
|
| Nocebo Effect | 1 | 2024 | 5 | 0.220 |
Why?
|
| Object Attachment | 2 | 2021 | 21 | 0.220 |
Why?
|
| Needs Assessment | 2 | 2018 | 174 | 0.220 |
Why?
|
| Incidence | 3 | 2014 | 1786 | 0.210 |
Why?
|
| Apathy | 1 | 2024 | 7 | 0.210 |
Why?
|
| Sex Distribution | 3 | 2011 | 177 | 0.210 |
Why?
|
| Postpartum Period | 1 | 2025 | 169 | 0.210 |
Why?
|
| Canada | 2 | 2017 | 210 | 0.210 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 40 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1784 | 0.200 |
Why?
|
| Terminology as Topic | 2 | 2015 | 225 | 0.200 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2018 | 337 | 0.200 |
Why?
|
| Consumer Behavior | 1 | 2004 | 35 | 0.200 |
Why?
|
| Prognosis | 4 | 2015 | 4126 | 0.200 |
Why?
|
| Narration | 1 | 2023 | 23 | 0.190 |
Why?
|
| Pain Measurement | 2 | 2007 | 401 | 0.190 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2023 | 16 | 0.190 |
Why?
|
| Brachytherapy | 1 | 2024 | 139 | 0.190 |
Why?
|
| Criminal Behavior | 1 | 2022 | 3 | 0.190 |
Why?
|
| Laser Therapy | 1 | 2024 | 149 | 0.190 |
Why?
|
| Chronic Disease | 3 | 2014 | 988 | 0.190 |
Why?
|
| Free Radical Scavengers | 2 | 2013 | 59 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 155 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 139 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 1303 | 0.190 |
Why?
|
| Remission Induction | 2 | 2015 | 758 | 0.180 |
Why?
|
| Genotype | 4 | 2015 | 1891 | 0.180 |
Why?
|
| Aripiprazole | 1 | 2022 | 8 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 7409 | 0.180 |
Why?
|
| Waiting Lists | 1 | 2004 | 237 | 0.180 |
Why?
|
| Psychophysiologic Disorders | 1 | 2001 | 5 | 0.170 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2001 | 4 | 0.170 |
Why?
|
| Culture | 2 | 2015 | 57 | 0.170 |
Why?
|
| Drug Monitoring | 2 | 2013 | 166 | 0.170 |
Why?
|
| Mass Screening | 2 | 2021 | 750 | 0.170 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 96 | 0.170 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 33 | 0.170 |
Why?
|
| Fathers | 1 | 2021 | 46 | 0.170 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 242 | 0.170 |
Why?
|
| Pirenzepine | 1 | 2001 | 6 | 0.170 |
Why?
|
| Models, Econometric | 2 | 2016 | 15 | 0.170 |
Why?
|
| Tourette Syndrome | 2 | 2018 | 24 | 0.170 |
Why?
|
| Gray Matter | 1 | 2021 | 48 | 0.170 |
Why?
|
| Developing Countries | 2 | 2020 | 101 | 0.170 |
Why?
|
| Parent-Child Relations | 1 | 2002 | 89 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2025 | 384 | 0.170 |
Why?
|
| Dopamine Agonists | 2 | 2014 | 28 | 0.160 |
Why?
|
| Irritable Mood | 1 | 2020 | 12 | 0.160 |
Why?
|
| Regression Analysis | 3 | 2018 | 577 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2024 | 381 | 0.160 |
Why?
|
| Secondary Prevention | 2 | 2013 | 185 | 0.160 |
Why?
|
| Outpatients | 3 | 2008 | 106 | 0.160 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 479 | 0.160 |
Why?
|
| Schools | 2 | 2011 | 95 | 0.160 |
Why?
|
| Safe Sex | 1 | 2020 | 24 | 0.160 |
Why?
|
| Program Evaluation | 2 | 2013 | 345 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2020 | 20 | 0.150 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 642 | 0.150 |
Why?
|
| Length of Stay | 1 | 2024 | 875 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 556 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2024 | 474 | 0.150 |
Why?
|
| Drug Approval | 1 | 2020 | 69 | 0.150 |
Why?
|
| Recreation | 2 | 2016 | 9 | 0.150 |
Why?
|
| Phobic Disorders | 3 | 2013 | 13 | 0.150 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 170 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 403 | 0.150 |
Why?
|
| Dementia | 1 | 2001 | 227 | 0.150 |
Why?
|
| Unsafe Sex | 1 | 2019 | 46 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2020 | 123 | 0.140 |
Why?
|
| Prescription Drug Diversion | 1 | 2018 | 1 | 0.140 |
Why?
|
| Connecticut | 2 | 2011 | 27 | 0.140 |
Why?
|
| Evaluation Studies as Topic | 2 | 2018 | 244 | 0.140 |
Why?
|
| Least-Squares Analysis | 1 | 2018 | 50 | 0.140 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2011 | 16 | 0.140 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2018 | 6 | 0.140 |
Why?
|
| Bias | 2 | 2022 | 140 | 0.140 |
Why?
|
| Anger Management Therapy | 1 | 2018 | 1 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 359 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2021 | 817 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1114 | 0.140 |
Why?
|
| Drug Users | 1 | 2018 | 33 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 50 | 0.140 |
Why?
|
| Australia | 3 | 2024 | 126 | 0.140 |
Why?
|
| Pregnancy | 1 | 2025 | 3266 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2001 | 418 | 0.130 |
Why?
|
| Forensic Psychiatry | 1 | 2017 | 7 | 0.130 |
Why?
|
| Social Media | 1 | 2020 | 119 | 0.130 |
Why?
|
| Delphi Technique | 2 | 2018 | 181 | 0.130 |
Why?
|
| Inflammation | 1 | 2024 | 1129 | 0.130 |
Why?
|
| Smoking Prevention | 2 | 2014 | 47 | 0.130 |
Why?
|
| Public Opinion | 1 | 2017 | 55 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 402 | 0.130 |
Why?
|
| Basal Ganglia | 1 | 2017 | 47 | 0.130 |
Why?
|
| Clomipramine | 1 | 2017 | 3 | 0.130 |
Why?
|
| Geriatric Psychiatry | 1 | 2017 | 18 | 0.130 |
Why?
|
| Neurotransmitter Agents | 2 | 2008 | 102 | 0.130 |
Why?
|
| Haplotypes | 1 | 2019 | 657 | 0.130 |
Why?
|
| Homosexuality, Male | 2 | 2014 | 342 | 0.130 |
Why?
|
| Employment | 2 | 2007 | 66 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 169 | 0.120 |
Why?
|
| Panic Disorder | 1 | 2016 | 21 | 0.120 |
Why?
|
| Online Systems | 1 | 2016 | 19 | 0.120 |
Why?
|
| Mental Health Services | 2 | 2018 | 97 | 0.120 |
Why?
|
| Affect | 2 | 2011 | 410 | 0.120 |
Why?
|
| Women's Rights | 1 | 2016 | 8 | 0.120 |
Why?
|
| Pacemaker, Artificial | 1 | 2017 | 119 | 0.120 |
Why?
|
| Financial Management | 1 | 2016 | 21 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 152 | 0.120 |
Why?
|
| Cognitive Remediation | 1 | 2015 | 2 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2017 | 160 | 0.120 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 18 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 131 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2018 | 258 | 0.110 |
Why?
|
| Hydrocortisone | 3 | 2007 | 305 | 0.110 |
Why?
|
| Consensus | 1 | 2017 | 308 | 0.110 |
Why?
|
| Heuristics | 1 | 2015 | 15 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2016 | 686 | 0.110 |
Why?
|
| Family Characteristics | 2 | 2008 | 52 | 0.110 |
Why?
|
| Focus Groups | 1 | 2016 | 214 | 0.110 |
Why?
|
| Interpersonal Relations | 2 | 2014 | 182 | 0.110 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 22 | 0.110 |
Why?
|
| Nervous System | 1 | 2015 | 92 | 0.110 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 192 | 0.110 |
Why?
|
| Body Weight | 2 | 2015 | 456 | 0.110 |
Why?
|
| Learning | 2 | 2018 | 311 | 0.110 |
Why?
|
| Drinking Behavior | 1 | 2014 | 13 | 0.110 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 20 | 0.110 |
Why?
|
| Animals | 6 | 2015 | 28950 | 0.110 |
Why?
|
| Perception | 1 | 2015 | 187 | 0.110 |
Why?
|
| Health Resources | 1 | 2015 | 80 | 0.110 |
Why?
|
| Foundations | 1 | 2014 | 15 | 0.110 |
Why?
|
| Discriminant Analysis | 1 | 2014 | 64 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 91 | 0.100 |
Why?
|
| Weight Loss | 2 | 2015 | 245 | 0.100 |
Why?
|
| Technology | 1 | 2014 | 31 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 660 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2575 | 0.100 |
Why?
|
| ROC Curve | 1 | 2016 | 793 | 0.100 |
Why?
|
| Science | 1 | 2014 | 39 | 0.100 |
Why?
|
| Public Policy | 1 | 2014 | 61 | 0.100 |
Why?
|
| Observer Variation | 2 | 2006 | 579 | 0.100 |
Why?
|
| Imagination | 1 | 2014 | 43 | 0.100 |
Why?
|
| Dangerous Behavior | 1 | 2013 | 6 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 155 | 0.100 |
Why?
|
| Recurrence | 2 | 2008 | 1261 | 0.100 |
Why?
|
| Pattern Recognition, Visual | 2 | 2012 | 159 | 0.100 |
Why?
|
| Probability | 1 | 2014 | 356 | 0.100 |
Why?
|
| Community Mental Health Centers | 1 | 2013 | 8 | 0.100 |
Why?
|
| Drug Therapy | 2 | 2006 | 67 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2017 | 602 | 0.100 |
Why?
|
| Sample Size | 1 | 2014 | 129 | 0.100 |
Why?
|
| Cognitive Dissonance | 1 | 2013 | 3 | 0.100 |
Why?
|
| Attitude to Computers | 1 | 2013 | 11 | 0.100 |
Why?
|
| Stroop Test | 1 | 2013 | 12 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 161 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2015 | 352 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2012 | 726 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 175 | 0.100 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 17 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2013 | 81 | 0.100 |
Why?
|
| Europe | 3 | 2018 | 356 | 0.090 |
Why?
|
| International Cooperation | 1 | 2013 | 132 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 2020 | 0.090 |
Why?
|
| Reversal Learning | 1 | 2012 | 19 | 0.090 |
Why?
|
| Denmark | 1 | 2012 | 21 | 0.090 |
Why?
|
| Cicatrix | 1 | 2012 | 78 | 0.090 |
Why?
|
| Germ-Line Mutation | 2 | 2025 | 402 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 107 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 137 | 0.090 |
Why?
|
| Systems Analysis | 1 | 2011 | 17 | 0.090 |
Why?
|
| Orientation | 1 | 2012 | 109 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 214 | 0.090 |
Why?
|
| Diet | 1 | 2015 | 469 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2002 | 192 | 0.090 |
Why?
|
| Family Therapy | 1 | 2011 | 18 | 0.080 |
Why?
|
| Health Behavior | 1 | 2013 | 202 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 198 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2012 | 245 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 630 | 0.080 |
Why?
|
| Income | 2 | 2018 | 101 | 0.080 |
Why?
|
| Causality | 1 | 2011 | 86 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2013 | 414 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 212 | 0.080 |
Why?
|
| Benzhydryl Compounds | 1 | 2010 | 47 | 0.080 |
Why?
|
| Self-Help Groups | 1 | 2009 | 15 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2013 | 402 | 0.070 |
Why?
|
| Marital Status | 1 | 2009 | 44 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 301 | 0.070 |
Why?
|
| Grooming | 1 | 2009 | 17 | 0.070 |
Why?
|
| Republic of Korea | 1 | 2009 | 41 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2023 | 153 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 311 | 0.070 |
Why?
|
| Propylamines | 1 | 2008 | 7 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2008 | 7 | 0.070 |
Why?
|
| Harm Reduction | 1 | 2009 | 36 | 0.070 |
Why?
|
| Alcoholic Intoxication | 1 | 2009 | 39 | 0.070 |
Why?
|
| Neural Inhibition | 1 | 2009 | 101 | 0.070 |
Why?
|
| Hygiene | 1 | 2007 | 12 | 0.070 |
Why?
|
| Amygdala | 1 | 2008 | 90 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2009 | 217 | 0.070 |
Why?
|
| Nicotine | 1 | 2009 | 218 | 0.060 |
Why?
|
| Poverty | 2 | 2020 | 214 | 0.060 |
Why?
|
| North America | 2 | 2018 | 210 | 0.060 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2006 | 24 | 0.060 |
Why?
|
| Amnesia | 1 | 2007 | 15 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2673 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2023 | 400 | 0.060 |
Why?
|
| Inpatients | 1 | 2010 | 367 | 0.060 |
Why?
|
| Epinephrine | 1 | 2006 | 91 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2020 | 387 | 0.060 |
Why?
|
| Awareness | 1 | 2007 | 93 | 0.060 |
Why?
|
| Bulimia | 1 | 2007 | 147 | 0.060 |
Why?
|
| Fructose | 1 | 2006 | 38 | 0.060 |
Why?
|
| Transaminases | 1 | 2006 | 32 | 0.060 |
Why?
|
| Social Control, Formal | 1 | 2005 | 10 | 0.060 |
Why?
|
| Arousal | 1 | 2006 | 177 | 0.060 |
Why?
|
| Nervous System Diseases | 2 | 2024 | 169 | 0.060 |
Why?
|
| Lifting | 2 | 1995 | 12 | 0.060 |
Why?
|
| Mesencephalon | 1 | 2006 | 68 | 0.060 |
Why?
|
| Algorithms | 3 | 2014 | 2001 | 0.060 |
Why?
|
| Religion | 1 | 2006 | 101 | 0.060 |
Why?
|
| Space Perception | 1 | 2007 | 113 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 94 | 0.060 |
Why?
|
| Receptors, Dopamine | 1 | 2005 | 32 | 0.060 |
Why?
|
| Risperidone | 1 | 2005 | 25 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 468 | 0.050 |
Why?
|
| Delay Discounting | 1 | 2024 | 10 | 0.050 |
Why?
|
| Caudate Nucleus | 1 | 2024 | 16 | 0.050 |
Why?
|
| Putamen | 1 | 2024 | 15 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 304 | 0.050 |
Why?
|
| beta-Endorphin | 1 | 2004 | 9 | 0.050 |
Why?
|
| London | 1 | 2004 | 15 | 0.050 |
Why?
|
| Prolactin | 1 | 2004 | 90 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 161 | 0.050 |
Why?
|
| Mobility Limitation | 1 | 2024 | 20 | 0.050 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 54 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2024 | 258 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2004 | 32 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 190 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2004 | 124 | 0.050 |
Why?
|
| Early Ambulation | 1 | 2024 | 31 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 58 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2024 | 325 | 0.050 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2023 | 13 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2004 | 228 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 41 | 0.050 |
Why?
|
| Visual Perception | 1 | 2007 | 341 | 0.050 |
Why?
|
| Sweden | 1 | 2023 | 49 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 354 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 608 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 120 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2004 | 513 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2002 | 23 | 0.050 |
Why?
|
| Guilt | 1 | 2002 | 11 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 96 | 0.050 |
Why?
|
| Psychopathology | 1 | 2002 | 31 | 0.050 |
Why?
|
| Transgender Persons | 1 | 2024 | 121 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 643 | 0.050 |
Why?
|
| Social Perception | 1 | 2003 | 93 | 0.040 |
Why?
|
| Varenicline | 1 | 2022 | 17 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 55 | 0.040 |
Why?
|
| Exploratory Behavior | 1 | 2002 | 48 | 0.040 |
Why?
|
| Utilization Review | 1 | 2001 | 23 | 0.040 |
Why?
|
| Smokers | 1 | 2022 | 64 | 0.040 |
Why?
|
| Psychological Theory | 1 | 2021 | 24 | 0.040 |
Why?
|
| Boredom | 1 | 2001 | 1 | 0.040 |
Why?
|
| Health Personnel | 1 | 2024 | 257 | 0.040 |
Why?
|
| Liver | 1 | 2006 | 1230 | 0.040 |
Why?
|
| Behavior | 1 | 2021 | 86 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2001 | 56 | 0.040 |
Why?
|
| Italy | 1 | 2021 | 113 | 0.040 |
Why?
|
| Critical Illness | 1 | 2024 | 361 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2024 | 4815 | 0.040 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2000 | 26 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 430 | 0.040 |
Why?
|
| Russia | 1 | 2020 | 29 | 0.040 |
Why?
|
| Attentional Bias | 1 | 2020 | 10 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 297 | 0.040 |
Why?
|
| Critical Care | 1 | 2024 | 462 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 420 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 191 | 0.040 |
Why?
|
| England | 1 | 2019 | 38 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2019 | 1 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 255 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 81 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2000 | 120 | 0.040 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2018 | 22 | 0.040 |
Why?
|
| South America | 1 | 2018 | 39 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 109 | 0.030 |
Why?
|
| Preliminary Data | 1 | 2018 | 2 | 0.030 |
Why?
|
| Controlled Before-After Studies | 1 | 2018 | 3 | 0.030 |
Why?
|
| Health Impact Assessment | 1 | 2018 | 2 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2000 | 253 | 0.030 |
Why?
|
| Libya | 1 | 2016 | 3 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 123 | 0.030 |
Why?
|
| Israel | 1 | 2016 | 68 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2010 | 94 | 0.030 |
Why?
|
| Hypochondriasis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2015 | 4026 | 0.030 |
Why?
|
| Intervertebral Disc Displacement | 1 | 1995 | 48 | 0.030 |
Why?
|
| Mice | 1 | 2009 | 12718 | 0.030 |
Why?
|
| Low Back Pain | 1 | 1995 | 62 | 0.030 |
Why?
|
| Alcohol Abstinence | 1 | 2014 | 7 | 0.030 |
Why?
|
| Inventions | 1 | 2014 | 16 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2014 | 93 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2014 | 65 | 0.030 |
Why?
|
| Politics | 1 | 2014 | 54 | 0.030 |
Why?
|
| Leadership | 1 | 2016 | 160 | 0.030 |
Why?
|
| Population Dynamics | 1 | 2014 | 149 | 0.020 |
Why?
|
| Paliperidone Palmitate | 1 | 2013 | 8 | 0.020 |
Why?
|
| Conservation of Natural Resources | 1 | 2014 | 102 | 0.020 |
Why?
|
| Climate Change | 1 | 2014 | 80 | 0.020 |
Why?
|
| Environment | 1 | 2014 | 233 | 0.020 |
Why?
|
| Knowledge Management | 1 | 2011 | 2 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 221 | 0.020 |
Why?
|
| Knowledge Bases | 1 | 2011 | 21 | 0.020 |
Why?
|
| Family Health | 1 | 2012 | 157 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 1995 | 376 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2002 | 239 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 3279 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2012 | 613 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2013 | 398 | 0.020 |
Why?
|
| Atrophy | 1 | 2010 | 131 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1147 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2010 | 188 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 1063 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2008 | 3 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 509 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2009 | 65 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2209 | 0.020 |
Why?
|
| Motor Cortex | 1 | 2010 | 210 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 68 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2010 | 242 | 0.020 |
Why?
|
| Catecholamines | 1 | 2007 | 93 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2007 | 166 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2007 | 58 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 74 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2006 | 74 | 0.010 |
Why?
|
| Work Capacity Evaluation | 2 | 1995 | 5 | 0.010 |
Why?
|
| Fluvoxamine | 1 | 2005 | 4 | 0.010 |
Why?
|
| Valproic Acid | 1 | 2005 | 25 | 0.010 |
Why?
|
| Lithium | 1 | 2005 | 61 | 0.010 |
Why?
|
| Antistreptolysin | 1 | 2004 | 1 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1858 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2007 | 794 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2004 | 260 | 0.010 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2000 | 19 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1944 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 138 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 901 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 1417 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2000 | 350 | 0.010 |
Why?
|
| Back Injuries | 1 | 1995 | 6 | 0.010 |
Why?
|
| Survival Rate | 1 | 2000 | 2050 | 0.010 |
Why?
|
| Body Constitution | 1 | 1995 | 26 | 0.010 |
Why?
|
| Ergonomics | 1 | 1995 | 26 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 1995 | 517 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2000 | 2687 | 0.000 |
Why?
|